Opioid medications have a complex and controversial role in managing non-cancer chronic pain.
The evidence for long-term opioid therapy in chronic non-cancer pain is limited as most studies showing benefit are short-term (less than 12 weeks), and there’s insufficient evidence that opioids improve long-term functional outcomes or quality of life.
Many patients experience diminishing pain relief over time due to tolerance.
Medical guidelines have shifted significantly toward more conservative opioid prescribing:
First-line treatments emphasize non-opioid medications, physical therapy, exercise, psychological interventions, and other multimodal approaches
Opioids are generally reserved for cases where other treatments have failed and only after careful risk-benefit assessment.
The lowest effective dose for the shortest duration necessary is used.
Long-term opioid use carries substantial risks: physical dependence, addiction, hormonal changes, increased fall risk, overdose potential, and opioid-induced hyperalgesia.
Some situations might be appropriate include severe osteoarthritis when surgery isn’t an option, certain neuropathic pain conditions unresponsive to other treatments, and acute flares of chronic conditions while awaiting other interventions.
Opioids are not recommended as first-line therapy for non-cancer pain.
Opioids role is limited to select cases where benefits for pain and function are expected to outweigh substantial risks, and even then, the magnitude of benefit is small and long-term efficacy is uncertain.
Compared with placebo, opioids provide only modest short-term reductions in pain intensity and slight improvements in physical functioning for chronic non-cancer pain, but these improvements are generally not clinically significant and are accompanied by increased risk of adverse effects such as vomiting, opioid use disorder, and overdose.
Guidelines recommend prioritizing nonpharmacologic and nonopioid pharmacologic therapies (e.g., NSAIDs, acetaminophen, antidepressants, exercise, CBT) due to their more favorable risk profiles.
Opioids should only be considered when other therapies have failed and after careful patient selection and risk assessment, and they should be combined with nonopioid and nonpharmacologic treatments if used.
Evidence for long-term benefit of beyond 6 months is lacking, and risks including tolerance, dependence, opioid-induced hyperalgesia, and serious adverse events—tend to increase with duration and dose.
If opioid use is deemed to be appropriate for use in non-cancer pain a plan for documenting therapeutic goals, monitoring, creating a schedule of dose reduction and managing potential withdrawal symptoms and providing non-opioid support should be instigated.